Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novavax Inc (NQ: NVAX )

11.29 +0.31 (+2.82%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novavax Inc

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Novavax Jumps After Pledging To Update Its Covid Shot; Pfizer, Moderna Slip
The FDA's experts voted in favor of annual boosters on Thursday. 
Via Investor's Business Daily
3 Great Growth Stocks Down 20% or More to Buy Now
These beaten-down stocks could be poised for major rebounds. 
Via The Motley Fool
This Investment Strategy Would Have Reduced Your Novavax Losses by 20% Last Year
If you want to invest in volatile stocks, a certain strategy can minimize your overall risk. 
Via The Motley Fool
3 Remarkable Stocks That Can Burn Short-Sellers Big-Time in 2023
Exceptionally high short interest in these innovative and transformative businesses may lead to a short squeeze. 
Via The Motley Fool
Could Novavax Stock Help You Become a Millionaire?
At such a beaten-down valuation, is the upside for Novavax just too significant to ignore? 
Via The Motley Fool
Here's the Worst Mistake Novavax Investors Can Make in 2023
Can Novavax still win over the long term? 
Via The Motley Fool
2 Down-on-Their-Luck Stocks That Could Go Parabolic
Any bit of good news could send these stocks soaring. 
Via The Motley Fool
With This Big Transition Ahead, Is Novavax a Buy?
Novavax stock sank 92% last year. 
Via The Motley Fool
What's Going On With Novavax Stock Today?
Novavax Inc (NASDAQ: NVAX) shares are trading higher Monday after the company announced a CEO transition. 
Via Benzinga
River Private Wealth announces new round of investment in Novavax, Inc
Via AB Newswire
3 Biotech Stocks Under $15 Worth a Second Look in 2023
All three stocks have promising therapies that could drive revenue in the coming years. 
Via The Motley Fool
Pfizer (PFE) Stock Falls on Analyst Downgrade
Although Pfizer led the charge in forwarding Covid-19 solutions, possibly waning relevancy poses serious concerns for PFE stock. 
Via InvestorPlace
If You Invested $1,000 in Novavax In 2020, This Is How Much You Would Have Today
The stock has gone on a wild ride over the past few years. 
Via The Motley Fool
Don't Blame the Bear Market for This Growth Stock's Jaw-Dropping Sell-Off
Novavax stock would likely have fallen in 2022 even in a bull market. 
Via The Motley Fool
2 Biotechs Making Waves With A Single Product in their Pipeline
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise. 
Via MarketBeat
HC Wainwright & Co. Maintains Buy Rating for Novavax: Here's What You Need To Know
 
Via Benzinga
Better Recovery Story Buy: Teladoc vs. Novavax
These stocks each sank more than 70% this year. 
Via The Motley Fool
Nasdaq Bear Market: 3 Remarkable Growth Stocks That Can Double Your Money in 18 Months
These innovative growth stocks have the tailwinds necessary to deliver triple-digit returns for their shareholders by mid-2024. 
Via The Motley Fool
NVAX Stock Alert: What to Know as Novavax Names New CEO
Although a change at the top boosted sentiment for Novavax, the harsh reality is that NVAX stock faces a mountain of worries. 
Via InvestorPlace
Why Is Ocugen (OCGN) Stock Up Today?
Ocugen is hoping its Indian-made inactivated Covid-19 shot can provide a low-cost boost for those previously given MRNA-based vaccines. 
Via InvestorPlace
Is Novavax Stock a Bargain After Falling More Than 90% From Its High?
Could the biotech be the ultimate contrarian buy of 2023? 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
How 'Covid Darling' Pfizer Became A 'Show Me' Story For 2023
Sales of Paxlovid and Comirnaty are expected to continue declining this year and next. 
Via Investor's Business Daily
Analyzing Novavax's Short Interest
Novavax's (NASDAQ:NVAX) short percent of float has fallen 4.15% since its last report. The company recently reported that it has 24.47 million shares sold short, which is 28.87% of all regular shares... 
Via Benzinga
US Stocks On Track To Start 2023 On Upbeat Note: Investors Shrug Off Past Year's Dismal Show And Pin Hopes On A Rebound
Trading in the U.S. index futures suggests that stocks may get off to a strong start in the first trading session of 2023. The mood is in contrast to the cautious outlook given by most Wall Street... 
Via Benzinga
7 Sensational Stocks That Can Double Your Money in 2023
Triple-digit returns could be just a click away from the buy button. 
Via The Motley Fool
What You Missed On Wall Street On Friday
In the midst of markets falling, some companies had good news, while others took a hit from analysts and a merger is still on hold. 
Via Talk Markets
2 Growth Stocks to Buy Heading Into 2023
These biotechs are far from having achieved their full potential. 
Via The Motley Fool
Novavax Kickstarts Phase 2 Trial For COVID-19-Flu Combo, Stand-Alone Flu Vaccine Candidates
 
Via Benzinga
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.